-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：Archer-Daniels-Midland (ADM)公佈了2026年第一季穩健的業績，調整後每股收益為0.71美元（同比增長1%），超出市場預期0.05美元。該公司將2026年全年業績預期從3.60美元至4.25美元上調至4.15美元至4.70美元（市場預期為4.23美元），主要得益於2026年3月即將最終確定的可再生燃料標準，該標準提供了至關重要的政策指引。這種監管確定性有利於生物燃料產業的發展，並強化了ADM的投資邏輯。碳水化合物解決方案業務表現突出，營業利潤飆升48%至3.56億美元，主要得益於乙醇業務受惠於政策環境改善帶來的利潤率提升。儘管受市值調整的影響，AS&O業務面臨不利因素，營業利潤下降34%至2.73億美元，但其基本營運績效展現出韌性。營養品業務持續維持復甦勢頭，營業利潤成長42%至1.35億美元。我們相信，監管環境的明朗化和強勁的營運執行力將使ADM在2026年之前實現獲利成長。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN